aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАНateroskleroz-652Research ArticleОБЗОРЫREVIEWSНазначение статинов у пациентов с гипотиреозом: возможные рискиThe appointment of statins in patients with hypothyroidism: possible risksРымарО. Д.RymarO D.

Оксана Дмитриевна Рымар, д-р мед. наук, ведущий научный сотрудник

СО РАМН

ФГБУ «НИИ терапии»

лаборатория клинико-популяционных и профилактических исследований терапевтических и эндокринных заболеваний,

630089

ул. Бориса Богаткова, 175/1

Новосибирск

SB RAMS

Establishment of the Russian Academy of Medical Sciences Research Institute of Therapy

630089

st. Boris Bogatkov, 175/1

Novosibirsk

orymar23@gmail.comМустафинаС. В.MustafinaS. V.

Светлана Владимировна Мустафина, канд. мед. наук, старший научный сотрудник

СО РАМН

ФГБУ «НИИ терапии»

лаборатории клинико-популяционных и профилактических исследований терапевтических и эндокринных заболеваний

630089

ул. Бориса Богаткова, 175/1

Новосибирск

SB RAMS

Establishment of the Russian Academy of Medical Sciences Research Institute of Therapy

630089

st. Boris Bogatkov, 175/1

Novosibirsk

svetlana3548@gmail.comМалышенкоЮ. А.MalyshenkoYa. A.

Юлия Александровна Малышенко, аспирант

СО РАМН

ФГБУ «НИИ терапии»

лаборатория клинико-популяционных и профилактическихисследований терапевтических и эндокринных заболеваний

630089

ул. Бориса Богаткова, 175/1

Новосибирск

SB RAMS

Establishment of the Russian Academy of Medical Sciences Research Institute of Therapy

630089

st. Boris Bogatkov, 175/1

Novosibirsk

doctor-yula@mail.ruРАМНRAMS201203042022823238Copyright © Рымар О.Д., Мустафина С.В., Малышенко Ю.А., 20222022Рымар О.Д., Мустафина С.В., Малышенко Ю.А.Rymar O.D., Mustafina S.V., Malyshenko Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/652

   Нарушения функции щитовидной железы и нарушения липидного обмена тесно связаны патогенетически. В течение последних лет обсуждается эффект L-тироксина на липидный профиль. По данным различных исследований, нормализация показателей липидного профиля происходит не во всех случаях при достижении эутиреоза. По данным литературы, посвященной пользе и риску применения статинов при гипотиреозе, декомпенсированный гипотиреоз может способствовать развитию миалгии и / или миозита, сопровождающихся повышением концентрации креатинфосфокиназы у больных, которые принимают статины. Есть несколько публикаций клинических случаев развития рабдомиолиза на фоне лечения статинами у лиц с недиагностированным, некомпенсированным манифестным гипотиреозом. Учитывая риск развития рабдомиолиза, практически во всех случаях следует оценивать уровень ТТГ до начала применения статинов.

   Thyroid dysfunction and dyslipidemia are closely connected by pathogenetic reason. During the last few years they have been discussing L-thyroxin influence on lipid profile. According to data obtained in various studies, lipid profile values normalization appears not in every case of euthyroidism. In the literature there is little information about statins administration risk and advantage during hypothyroidism. According to the literature, decompensated hypothyroidism can lead to myalgia and / or myopathy development accompanied by creatine phosphokinase concentration increase in patients on statins. There are several publications of clinical cases of rhabdomyolysis development against the statins treatment background in persons with undiagnosed decompensated manifest hypothyroidism. Thus, taking into account the risk of the rhabdomyolysis development, TSH level should be estimated before statins treatment almost in all cases.

гипотиреозстатиныL-тироксинрабдомиолизщитовидная железаhypothyroidismstatinsL-thyroxinrhabdomyolysisthyroidReferencesGupta A., Sinha R. S. Echocardiographic changes and alterations in lipid profile in cases of subclinical and overt hypothyroidism // J. Assoc. Physicians India. 1996. Vol. 44. P. 546, 551–553.Gupta A., Sinha R. S. Echocardiographic changes and alterations in lipid profile in cases of subclinical and overt hypothyroidism // J. Assoc. Physicians India. 1996. Vol. 44. P. 546, 551–553.Hak A. E., Pols H., Visser T. J. et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women the Rotterdam study // Ann. Intern. Med. 2000. Vol. 132, N 4. P. 270–278.Hak A. E., Pols H., Visser T. J. et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women the Rotterdam study // Ann. Intern. Med. 2000. Vol. 132, N 4. P. 270–278.Michalopoulou G., Alevizaki M., Piperingos G. et al. High serum cholesterol levels in persons with ‘high-normal’ TSH levels: should one extend the definition of subclinical hypothyroidism?// Eur. J. Endocrinol. 1998. Vol. 138, N 2. Р. 141–145.Michalopoulou G., Alevizaki M., Piperingos G. et al. High serum cholesterol levels in persons with ‘high-normal’ TSH levels: should one extend the definition of subclinical hypothyroidism?// Eur. J. Endocrinol. 1998. Vol. 138, N 2. Р. 141–145.Diekman T., Lansberg P. J., Kastelein J. J. et al. Prevalence and correction of hypothyroidism in a large cohort of patients refered for dyslipidemia // Arch. Intern. Med. 1995. Vol. 155, N 14. Р. 1490–1495.Diekman T., Lansberg P. J., Kastelein J. J. et al. Prevalence and correction of hypothyroidism in a large cohort of patients refered for dyslipidemia // Arch. Intern. Med. 1995. Vol. 155, N 14. Р. 1490–1495.Duntas L. H. Thyroid disease and lipids // Thyroid. 2002. Vol. 12. P. 287–293.Duntas L. H. Thyroid disease and lipids // Thyroid. 2002. Vol. 12. P. 287–293.Franklyn J. A., Daykin J., Betteridge J. et al. Sheppard Thyroxine replacement therapy and circulating lipid concentrations // Clin. Endocrinol. 1993. Vol. 38, N 5. Р. 453–459.Franklyn J. A., Daykin J., Betteridge J. et al. Sheppard Thyroxine replacement therapy and circulating lipid concentrations // Clin. Endocrinol. 1993. Vol. 38, N 5. Р. 453–459.Caron P., Calazel С., Parra H. J. et al. Decreased HDL cholesterol in subclinikal hypothyroidism: the effect of L-thyroxine therapy // J. Clin. Endocrinol. 1990. Vol. 33. P. 519–523.Caron P., Calazel С., Parra H. J. et al. Decreased HDL cholesterol in subclinikal hypothyroidism: the effect of L-thyroxine therapy // J. Clin. Endocrinol. 1990. Vol. 33. P. 519–523.Althaus B. U., Staub J. J., De Luche A. R. et al. LDL / HDL-changes in subclinical hypothyroidism:possible risk factors for coronary artery disease // Clin. Endocrinol. 1988. Vol. 28. P. 157–163.Althaus B. U., Staub J. J., De Luche A. R. et al. LDL / HDL-changes in subclinical hypothyroidism:possible risk factors for coronary artery disease // Clin. Endocrinol. 1988. Vol. 28. P. 157–163.Park K. W., Dai H. B., Ojamaa K. et al. The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries // Anesth. Analg. 2002. Vol. 85. P. 734–738.Park K. W., Dai H. B., Ojamaa K. et al. The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries // Anesth. Analg. 2002. Vol. 85. P. 734–738.Фадеев В. В. Заболевания щитовидной железы в регионе легкого йододефицита: эпидемиология, диагностика, лечение / В. В. Фадеев. – М.: Видар, 2005. – 238 с.Фадеев В. В. Заболевания щитовидной железы в регионе легкого йододефицита: эпидемиология, диагностика, лечение / В. В. Фадеев. – М.: Видар, 2005. – 238 с.Tanis B. C., Westendop R. G. J., Smelt A. H. M. Effect of thyroid substitution on hypercholesterolemia in patients with subclinical hypothyroidism: A reanalysis of intervention studies // Clin. Endocrinol. 1996. Vol. 44, N 6. P. 643–649.Tanis B. C., Westendop R. G. J., Smelt A. H. M. Effect of thyroid substitution on hypercholesterolemia in patients with subclinical hypothyroidism: A reanalysis of intervention studies // Clin. Endocrinol. 1996. Vol. 44, N 6. P. 643–649.Wiseman S. A., Powell J. T., Humphries S. E., Press M. The magnitude of the hypercholesterolemia of hypothyroidism is associated with variation in the low density lipoprotein receptor gene // J. Clin. Endocrinol. Metab. 1993. Vol. 72, N 1. P. 108–112.Wiseman S. A., Powell J. T., Humphries S. E., Press M. The magnitude of the hypercholesterolemia of hypothyroidism is associated with variation in the low density lipoprotein receptor gene // J. Clin. Endocrinol. Metab. 1993. Vol. 72, N 1. P. 108–112.Caracio N., Ferrannini E., Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controiier stydy// J. Clin. Endocrinol. Metab. 2002. Vol. 87. P. 1533–1538.Caracio N., Ferrannini E., Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controiier stydy// J. Clin. Endocrinol. Metab. 2002. Vol. 87. P. 1533–1538.Mya M. M., Aronow W. S., Gerontol A. Subclinical hypothyroidism is associated with coronary artery disease in older persons // Biol. Sci. Med. Sci. 2002. Vol. 57, N 10. P. 658–659.Mya M. M., Aronow W. S., Gerontol A. Subclinical hypothyroidism is associated with coronary artery disease in older persons // Biol. Sci. Med. Sci. 2002. Vol. 57, N 10. P. 658–659.Kim S. K., Kim S. H., Park K. S. et al. Regression of the increased common carotid artery-intima media thickness in subclinical hypothyroidism after thyroid hormone replacement // Endocr. J. 2009. Vol. 56, N 6. Р. 753–758.Kim S. K., Kim S. H., Park K. S. et al. Regression of the increased common carotid artery-intima media thickness in subclinical hypothyroidism after thyroid hormone replacement // Endocr. J. 2009. Vol. 56, N 6. Р. 753–758.Мустафина С. В. Функциональное состояние щитовидной железы и липидный профиль / С. В. Мустафина [и др.] // Атеросклероз. – 2010. – Т. 6, № 2. – С. 15–20.Мустафина С. В. Функциональное состояние щитовидной железы и липидный профиль / С. В. Мустафина [и др.] // Атеросклероз. – 2010. – Т. 6, № 2. – С. 15–20.Tomlinson B., Lan W. Hypothyroidism and simvastatin // HKMJ. 2001. Vol. 7, N 2. P. 219–220.Tomlinson B., Lan W. Hypothyroidism and simvastatin // HKMJ. 2001. Vol. 7, N 2. P. 219–220.Товажнянская Е. Л. Аторвастатин в лечении больных первичным гипотиреозом с неврологическими осложнениями и гиперлипидемией / Е. Л. Товажнянская // Междунар. мед. журн. – 2008. – № 2. – C. 22–26.Товажнянская Е. Л. Аторвастатин в лечении больных первичным гипотиреозом с неврологическими осложнениями и гиперлипидемией / Е. Л. Товажнянская // Междунар. мед. журн. – 2008. – № 2. – C. 22–26.Hung Y. T., Yeung V. T. F. Hypothyroidism presenting as hypercholesterolaemia and simvastatin-induced myositis // HKMJ. 2000. N 6. Р. 423–424.Hung Y. T., Yeung V. T. F. Hypothyroidism presenting as hypercholesterolaemia and simvastatin-induced myositis // HKMJ. 2000. N 6. Р. 423–424.Hamilton C. I. Statin-associated myopathy // Med. J. Aust. 2001. Vol. 175, N 9. Р. 486–489.Hamilton C. I. Statin-associated myopathy // Med. J. Aust. 2001. Vol. 175, N 9. Р. 486–489.Lang J., Wang P., Glueck C. Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism // Clin. Chim. Acta. 1996. Vol. 254. P. 65–92.Lang J., Wang P., Glueck C. Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism // Clin. Chim. Acta. 1996. Vol. 254. P. 65–92.Lin R. T., Liu C. K., Tai C. T. et al. Hypothyroid myopathy – pathological and ultrastructural study // Kaohsiung J. Med. Sci. 2000. N 16. Р. 68–75.Lin R. T., Liu C. K., Tai C. T. et al. Hypothyroid myopathy – pathological and ultrastructural study // Kaohsiung J. Med. Sci. 2000. N 16. Р. 68–75.Prudhomme F., Jacotot B. Muscular toxicity of antilipemic agents revealed during the course of hypothyroidism // Presse Med. 2003. N 32. Р. 1031–1032.Prudhomme F., Jacotot B. Muscular toxicity of antilipemic agents revealed during the course of hypothyroidism // Presse Med. 2003. N 32. Р. 1031–1032.Łukjanowicz M., Trzcińska-Butkiewicz B., Brzosko M. Miopatia spowodowana stosowaniem fenofibratu u osoby z nierozpoznaną niedoczynnością tarczycy – opis przypadku i przegląd piśmiennictwa // Pol. Arch. Med. Wewn. 2006. Vol. 115. P. 45–49.Łukjanowicz M., Trzcińska-Butkiewicz B., Brzosko M. Miopatia spowodowana stosowaniem fenofibratu u osoby z nierozpoznaną niedoczynnością tarczycy – opis przypadku i przegląd piśmiennictwa // Pol. Arch. Med. Wewn. 2006. Vol. 115. P. 45–49.Thompson P. D., Clarkson P., Karas R. H. Statin-associated myopathy // JAMA. 2003. Vol. 289. Р. 1681–1690.Thompson P. D., Clarkson P., Karas R. H. Statin-associated myopathy // JAMA. 2003. Vol. 289. Р. 1681–1690.Law M., Rudnicka A. R. Statin safety: a systematic review // Am. J. Cardiol. 2006. Vol. 97, N 8A. Р. 52–60.Law M., Rudnicka A. R. Statin safety: a systematic review // Am. J. Cardiol. 2006. Vol. 97, N 8A. Р. 52–60.Lindner A., Zierz S. Rhabdomyolysis and myoglobinuria// Nervenarzt. 2003. Vol. 74, N 6. Р. 505–515.Lindner A., Zierz S. Rhabdomyolysis and myoglobinuria// Nervenarzt. 2003. Vol. 74, N 6. Р. 505–515.Pasternak R. C., Smith S. C., Bairey-Merz C. N. et al. ACC / AHA / NHLBI clinical advisory on the use and safety of statins // J. Am. Coll. Cardiol. 2002. N 40. Р. 567–572.Pasternak R. C., Smith S. C., Bairey-Merz C. N. et al. ACC / AHA / NHLBI clinical advisory on the use and safety of statins // J. Am. Coll. Cardiol. 2002. N 40. Р. 567–572.Omar M. A., Willson J. P., Cox T. S. Rhabdomyolysis and HMG-COA reductase inhibitors // Ann Pharmacother. 2001. Vol. 35. P. 1096–1107.Omar M. A., Willson J. P., Cox T. S. Rhabdomyolysis and HMG-COA reductase inhibitors // Ann Pharmacother. 2001. Vol. 35. P. 1096–1107.Barahona M. J., Mauri A., Sucuzza N. et al. Hypothroidism as a cause of Rhabdomyolysis // Endocr. J. 2002. N 49. Р. 621–623.Barahona M. J., Mauri A., Sucuzza N. et al. Hypothroidism as a cause of Rhabdomyolysis // Endocr. J. 2002. N 49. Р. 621–623.Mc Kenney J. M. An Assessment of Statin Safety // Am. J. Manag. Care. 2006. N 12. Р. 310–317.Mc Kenney J. M. An Assessment of Statin Safety // Am. J. Manag. Care. 2006. N 12. Р. 310–317.Thompson P. D., Clarkson P. M., Rosenson R. S. An Assessment of Statin Safety by Muscle Experts // Am. J. Cardiol. 2006. Vol. 97, N 8. P. 69–76.Thompson P. D., Clarkson P. M., Rosenson R. S. An Assessment of Statin Safety by Muscle Experts // Am. J. Cardiol. 2006. Vol. 97, N 8. P. 69–76.Ronaldson K. J., O’Shea J. M., Boyd I. W. Risk factors for rhabdomyolysis with simvastatin and atorvastatin // Drug Saf. 2006. Vol. 29, N 11. Р. 1061–1067.Ronaldson K. J., O’Shea J. M., Boyd I. W. Risk factors for rhabdomyolysis with simvastatin and atorvastatin // Drug Saf. 2006. Vol. 29, N 11. Р. 1061–1067.«Interaction between amiodarone (marketed as Zocor and generics) or Simvastatin-combination products (marketed as Vytorin and Simcor): Amiodarone potentiates the risk for simvastatin-associated rhabdomyolysis» // Drug Safety Newsletter, Summer 2008. Vol. 1, N 4.«Interaction between amiodarone (marketed as Zocor and generics) or Simvastatin-combination products (marketed as Vytorin and Simcor): Amiodarone potentiates the risk for simvastatin-associated rhabdomyolysis» // Drug Safety Newsletter, Summer 2008. Vol. 1, N 4.Tokinaga K., Oeda T., Suziki Y., Matsushima Y. HMG CoA Reductase Inhibitors might ause high elevations of creatine phosphokinase in patients with unnoticed hypothyroidism // Endocr. J. 2006. Vol. 53. P. 401–405.Tokinaga K., Oeda T., Suziki Y., Matsushima Y. HMG CoA Reductase Inhibitors might ause high elevations of creatine phosphokinase in patients with unnoticed hypothyroidism // Endocr. J. 2006. Vol. 53. P. 401–405.Yeter E., Keles T., Durmaz T., Bozkurt E. Rhabdomyolysis due to the additive effect of statin therapy and hypothyroidism: a case report // J. Med. Case Reports. 2007. 1: 130 doi:10.1186/1752-1947-1-130Yeter E., Keles T., Durmaz T., Bozkurt E. Rhabdomyolysis due to the additive effect of statin therapy and hypothyroidism: a case report // J. Med. Case Reports. 2007. 1: 130 doi:10.1186/1752-1947-1-130Finsterer J. Fibrat / Statin – Myopathie// Nervenarzt. 2003. Vol. 74. P. 115–122.Finsterer J. Fibrat / Statin – Myopathie// Nervenarzt. 2003. Vol. 74. P. 115–122.Simona L., Bar D. T., Holmes J. F. Asymptomatic hypothyroidism and statin-induced myopathy// Canadian Family Physician. 2007. Vol. 53. Р. 428–431.Simona L., Bar D. T., Holmes J. F. Asymptomatic hypothyroidism and statin-induced myopathy// Canadian Family Physician. 2007. Vol. 53. Р. 428–431.Kędzia A., Krysiak R., Madej A., Okopień B. Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? // Polskie archiwum medycyny wewnetrznej. 2007. Vol. 117, N 10. Р. 473–476.Kędzia A., Krysiak R., Madej A., Okopień B. Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? // Polskie archiwum medycyny wewnetrznej. 2007. Vol. 117, N 10. Р. 473–476.

The authors declare that there are no conflicts of interest present.